Pharmaceutical management of COPD.

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.authorLee, Po-Lin
dc.contributor.departmentDE--Általános Orvostudományi Kar
dc.contributor.opponentDrimba, László
dc.contributor.opponentMegyeri, Attila
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Aneszteziológiai és Intenzív Terápiás Tanszék
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.date.accessioned2023-08-09T11:04:40Z
dc.date.available2023-08-09T11:04:40Z
dc.date.created2023-05-20
dc.description.abstractChronic obstructive pulmonary disease (COPD) is a progressive respiratory condition characterized by persistent airflow limitation and chronic inflammation of the airways. It is a major cause of morbidity and mortality worldwide. While nonpharmacological interventions play a crucial role in COPD management, pharmacological therapies are essential for symptom control, prevention of exacerbations, and improving overall quality of life. This review provides an overview of the pharmacological management of COPD, including bronchodilators, inhaled corticosteroids, combination therapies, and emerging treatments. Bronchodilators, such as long-acting β2-agonists and long-acting anticholinergics, are the mainstay of COPD treatment, offering bronchodilation and symptom relief. Inhaled corticosteroids may be considered in patients with frequent exacerbations or eosinophilic inflammation. Combination therapies, combining bronchodilators and corticosteroids, have shown improved efficacy in certain patient populations. Novel treatments, such as phosphodiesterase-4 inhibitors and monoclonal antibodies targeting specific inflammatory pathways, are being explored to further optimize COPD management. Additionally, smoking cessation, pulmonary rehabilitation, and adherence to prescribed medications are crucial components of comprehensive COPD care. Personalized treatment strategies based on disease severity, phenotype, and patient preferences are increasingly emphasized. Healthcare providers should consider individualizing therapy and regularly assessing treatment response to optimize outcomes in COPD patients. Further research and clinical trials are needed to expand the armamentarium of pharmacological options and improve the long-term outcomes in COPD management.
dc.description.correctorLB
dc.description.courseáltalános orvos
dc.description.courselangangol
dc.description.coursespecOrvosbiológia-farmakológia
dc.description.degreeegységes, osztatlan
dc.format.extent56
dc.identifier.urihttps://hdl.handle.net/2437/358111
dc.language.isoen
dc.rights.accessHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.
dc.subjectCOPD treatment
dc.subject.dspaceDEENK Témalista::Orvostudomány::Farmakológia
dc.titlePharmaceutical management of COPD.
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)